Cytotherapy · Nov 2026

A Genetically Engineered, Monoclonal, and Inducible Mesenchymal Stem Cell Platform with Controlled Proliferation and In Vivo Traceability

By Massumi M, Owji H, Yang G et al.

Mesenchymal stem cells (MSCs) are widely explored for regenerative medicine, tissue engineering, and targeted cancer therapy due to their multipotency, immunomodulatory properties, and intrinsic tropism toward injured and tumor tissues. However, the application of MSC-based therapies remains restricted by several key challenges, including limited replicative lifespan, donor-to-donor variability, polyclonality, and the inability to track administered cells in real time in vivo. To address these barriers, we developed a conditionally immortalized, monoclonal, and traceable adipose-derived MSC (ASC) platform designed for safe, scalable, and reproducible biomedical applications. Primary ASCs from a female donor were genetically engineered to conditionally express human telomerase reverse transcriptase (hTERT), nanoluciferase (nLuc), and green fluorescent protein (GFP) under the control of a doxycycline (Dox)-inducible Tet-On system. Using a stringent three-step positive–negative–positive sorting strategy, we isolated a single monoclonal ASC line (iASC2) whose proliferation was tightly regulated by low-dose Dox. The iASC2 monoclone maintained hallmark MSC characteristics, including tissue culture plate adherence, expression of canonical MSC surface markers, and multilineage differentiation capacity. Dox induction rescued cells from replicative senescence at late passages and significantly increased proliferation rates, while withdrawal of Dox suppressed hTERT expression and cell expansion. Real-time in vivo bioluminescent imaging demonstrated that implanted iASC2 remained viable, localized, and non-tumorigenic for over four months in triple-immunodeficient mice. Histological analyses confirmed differentiation of iASC2 monoclone into mesenchymal lineages without evidence of malignant transformation. Importantly, iASC2 monoclone preserved their ability to sense and migrate toward chemokines secreted from tumor cells in vitro and in vivo, a critical feature for targeted therapeutic delivery. Collectively, this study establishes a conditionally immortalized, monoclonal, and traceable MSC platform that overcomes some of the key limitations of existing MSC-based systems. The iASC2 monoclone represents a standardized cell source that could potentially serve as a delivery vehicle for biologics in applications such as cancer therapy, monogenic disorders, and autoimmune diseases.

doi.org/10.1016/j.jcyt.2026.103066Open accessInterventions

AgingResearch.News